2019
DOI: 10.1002/phar.2203
|View full text |Cite
|
Sign up to set email alerts
|

Plazomicin: A Next‐Generation Aminoglycoside

Abstract: Plazomicin is a novel aminoglycoside antibiotic that binds to the bacterial 30S ribosomal subunit, thus inhibiting protein synthesis in a concentration‐dependent manner. Plazomicin displays a broad spectrum of activity against aerobic gram‐negative bacteria including extended‐spectrum β‐lactamase–producing Enterobacteriaceae, carbapenem‐resistant Enterobacteriaceae, and organisms with aminoglycoside‐modifying enzymes. In a large phase III clinical trial, plazomicin was shown to be noninferior to meropenem in t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
41
0
2

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 74 publications
(43 citation statements)
references
References 42 publications
0
41
0
2
Order By: Relevance
“…The evolution of β-lactam resistance among Enterobacteriaceae, Pseudomonas aeruginosa , and Acinetobacter spp., has forced clinicians to resort to antimicrobial agents that have poorly defined pharmacokinetic/pharmacodynamic (PK/PD) targets, as well as significant toxicity which limit their reliability in infection eradication [ 1 , 3 ]. Plazomicin (formerly ACHN-490), a neoglycoside, has demonstrated activity against Gram-negative bacteria expressing a wide range of resistance mechanisms [ 4 ]. Aminoglycosides (AGs) are broad spectrum, bactericidal, antibiotics used for treating complicated urinary tract infections (cUTIs), nosocomial respiratory tract infections, and septicemia.…”
Section: Introductionmentioning
confidence: 99%
“…The evolution of β-lactam resistance among Enterobacteriaceae, Pseudomonas aeruginosa , and Acinetobacter spp., has forced clinicians to resort to antimicrobial agents that have poorly defined pharmacokinetic/pharmacodynamic (PK/PD) targets, as well as significant toxicity which limit their reliability in infection eradication [ 1 , 3 ]. Plazomicin (formerly ACHN-490), a neoglycoside, has demonstrated activity against Gram-negative bacteria expressing a wide range of resistance mechanisms [ 4 ]. Aminoglycosides (AGs) are broad spectrum, bactericidal, antibiotics used for treating complicated urinary tract infections (cUTIs), nosocomial respiratory tract infections, and septicemia.…”
Section: Introductionmentioning
confidence: 99%
“…Very recent studies further provide promising perspectives in the combat of infections with MDR pathogens. For instance, the new aminoglycoside plazomicin showed broad antimicrobial effects against Gram-negative bacteria, including carbapenemase-producing strains [ 41 ]. This pharmacological review article described the effects of plazomicin in complicated urinary tract infections, mostly effective against carbapenem-resistant K. pneumoniae , including KPC-positive pathogens, based on clinical trials [ 42 ].…”
Section: Discussionmentioning
confidence: 99%
“…Plazomicin is a newly developed aminoglycoside antimicrobial which inhibits microbial protein synthesis by binding with the microbial 30S ribosomal subunit in a concentration-dependent manner. Plazomicin exhibits a broad spectrum of activity against aerobic gram-negative pathogens including extended-spectrum β-lactamase–producing (ESBL) Enterobacteriaceae , CRE, and microorganisms capable of producing aminoglycoside-modifying enzymes ( 148 , 149 ). Plazomicin resistant to those pathogens are encoded with 16S ribosomal RNA methyl-transferases (16S-RMTases) especially for Enterobacteriaceae spp ( 150 154 ).…”
Section: History Of Antibiotics In the Last Millenniummentioning
confidence: 99%